^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-DOTA-EB-FAPI

    i
    Other names: 177Lu-DOTA-EB-FAPI
    Associations

    News

    Trials
    Company:
    Xiamen University
    Drug class:
    FAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients with Various Solid Tumors (clinicaltrials.gov)
    P2, N=28, Completed, The First Affiliated Hospital of Xiamen University | Recruiting --> Completed | Phase classification: P1 --> P2 | N=20 --> 28 | Trial completion date: Jun 2025 --> Oct 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
    Trial completion • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    177Lu-DOTA-EB-FAPI
    over1year
    Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, The First Affiliated Hospital of Xiamen University | Phase classification: P2 --> P1
    Phase classification • Metastases
    |
    FAP (Fibroblast activation protein, alpha)
    |
    177Lu-DOTA-EB-FAPI
    over2years
    Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FAP (Fibroblast activation protein, alpha)
    |
    177Lu-DOTA-EB-FAPI